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Abstract
The impact of sex and menopausal status in Alzheimer’s disease remains under-
studied despite increasing evidence of greater female risk, particularly in APOE4 
carriers. Utilizing female APOE- TR mice maintained on a high- fat diet background 
we induced ovarian failure through repeated VCD injections, to mimic human meno-
pause. At 12 months of age, recognition memory and spatial memory were assessed 
using object recognition, Y- maze spontaneous alternation, and Barnes maze. A 
VCD*genotype interaction reduced the recognition memory (P < .05), with APOE4 
VCD- treated animals unable to distinguish between novel and familiar objects. 
APOE4 mice displayed an additional 37% and 12% reduction in Barnes (P < .01) 
and Y- maze (P < .01) performance, indicative of genotype- specific spatial memory 
impairment. Molecular analysis indicated both VCD and genotype- related deficits 
in synaptic plasticity with BDNF, Akt, mTOR, and ERK signaling compromised. 
Subsequent reductions in the transcription factors Creb1 and Atf4 were also evident. 
Furthermore, the VCD*genotype interaction specifically diminished Ephb2 expres-
sion, while Fos, and Cnr1 expression reduced as a consequence of APOE4 genotype. 
Brain DHA levels were 13% lower in VCD- treated animals independent of genotype. 
Consistent with this, we detected alterations in the expression of the DHA transport-
ers Acsl6 and Fatp4. Our results indicate that the combination of ovarian failure and 
APOE4 leads to an exacerbation of cognitive and neurological deficits.
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1 |  INTRODUCTION
The development of sporadic late- onset Alzheimer’s disease 
(AD) is complex and multifactorial with more than 20 sus-
ceptibility loci including Apolipoprotein E (APOE).1 APOE4 
is the strongest prevalent genetic risk factor with an allele fre-
quency of 14% in the general population and is concentrated 
in AD (allele frequency ~40% in Caucasians).2 The APOE4 
gene increases AD risk in a gene dose- dependent manner, ris-
ing from 2- to 3- fold for heterozygous APOE4 carriers and 
12- fold in homozygotes,3,4 with age of onset considerably re-
duced. However, a large proportion of APOE4 carriers do not 
develop AD indicating that the genotype is predictive rather 
than prognostic and may be modulated by other environmental 
and biological factors.5 There is accumulating evidence that the 
penetrance of APOE4 genotype is influenced by sex,4,6 which 
may underlie the finding that almost two thirds of AD cases 
are females.7 In a large meta- analysis Neu and colleagues re-
ported increased MCI and AD risk in females compared to 
male APOE4 carriers between 55- 70 years and 65- 75 years, 
respectively.8 Despite this observation, little is known of the 
etiology underlying this susceptibility. However, given the age 
at which females are at increased risk8 and the fact that earlier 
onset of menopause correlates with poorer cognition in later 
life,9 it is plausible that menopause acts as a mediating factor.
Within the central nervous system APOE is the main lipid 
transporter.10 In comparison to other organs, the brain is highly 
enriched with the n- 3 polyunsaturated fatty acid (PUFA) do-
cosahexaenoic acid (DHA) accounting for ~15% of total brain 
lipids.11 We have recently reported lower DHA and specialized 
pro- resolving mediators in old APOE4 female mice, indicat-
ing how sex, APOE4, and age contribute to the development 
of cognitive decline and AD pathology.12 DHA is specifically 
concentrated within synaptosomal membranes,13 influencing 
membrane dynamics, membrane protein function, secondary 
messenger systems, and neurotransmitter concentrations.14 
Thus it is unsurprising that reduced DHA status is consistently 
linked to poorer cognitive outcome and increased AD risk.15 
Synaptic loss and dysfunction which has been characterized in 
both menopause and APOE4 individuals, is directly associated 
with cognitive decline and occurs in the initial stages of AD.16
With an etiological link accounting for the greater female 
APOE4 susceptibility distinctly lacking,17 we posit menopause 
as a contributing factor, given the neuroprotective properties of 
estrogen,18 and greater cognitive decline associated with early 
menopause.9 Here, in a transgenic mouse model we assessed 
the combined impact of APOE genotype and ovarian failure 
on cognitive performance hypothesizing that APOE4 animals 
will be more susceptible to estrogen loss. Furthermore, we 
determine if changes in cognitive performance relate to alter-
ations in brain fatty acid profiles and synaptic plasticity. Our 
model system combines the humanized- targeted replacement 
(APOE- TR) mouse model with 4- vinylcyclohexene diepoxide 
(VCD) treatment credited for its ability to establish an inter-
mediary human- like “perimenopause” phase, while maintain-
ing ovarian tissue integrity.19
2 |  MATERIALS AND METHODS
2.1 | Study approval
All experimental procedures and protocols used in this 
study were reviewed and approved by the Animal Welfare 
and Ethical Review Body (AWERB) and were conducted 
within the provisions of the Home Office Animals (Scientific 
Procedures) Act 1986.
2.2 | Animal model and experimental design
Forty eight C57BL/6 background female humanized 
APOE3 (B6.129P2- Apoetm2(APOE*3)Mae N8) and APOE4 
(B6.129P2- Apoetm2(APOE*4)Mae N8)- targeted replacement 
mice homozygous for the human APOE3 or APOE4 gene 
(Taconic, Germantown, NY, USA) were used in these ex-
periments.12,20,21 Mice were maintained in a controlled envi-
ronment (21 ± 2°C; 12- h light- dark cycle; light from 07:00 
hours) and fed ad libitum on a standard chow diet (RM3- P, 
Special Diet Services, Essex, UK) until the age of 4 months, 
ensuring normal development. Following this run- in period, 
mice were switched to a semi- purified high- fat diet (45 kCal% 
fat) (D17080301, Research diets, New Brunswick, NJ, USA) 
for the remaining duration of the experiment (See Table S1 
for full dietary composition). A high- fat diet was utilized to 
mimic a human “western- style” high- fat diet and exacerbate 
AD age- related cognitive decline.22
At 8 months of age and to assess the impact of meno-
pause, mice from each genotype received intra peritoneal 
(i.p.) injections of either VCD (160 mg/kg body weight) di-
luted in sesame oil, or sesame oil vehicle (sham) for a total of 
14 injections over 3 weeks. The VCD model system is a well- 
established method for inducing a “menopause” like state in 
rodents23 and is well- tolerated leading to a targeted degra-
dation of ovarian follicles.24 Eight months was selected as it 
is roughly midlife for the animals (when human menopause 
occurs) and before natural ovarian failure is known to occur 
in C57BL/6 mice.25,26 Following completion of the final 
behavioral test, 12- month aged animals were sedated with 
isoflurane (1.5%) in a mixture of nitrous oxide (70%), and 
oxygen (30%) and transcardially perfused with an ice- cold 
PBS- containing protease (SIGMAFAST Protease inhibitor, 
Sigma- Aldrich, Devon, UK) and phosphatase (1 mM sodium 
pyrophosphate and 50 mM sodium fluoride, Sigma- Aldrich, 
Devon, UK) inhibitors. Sera were isolated via centrifugation 
at 2,000 ×g for 10 minutes. Brains were rapidly removed, 
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halved, snap frozen, and stored at −80°C until biochemical 
analysis. Ovaries were rapidly removed and processed for 
histology (see Section 2.4). Graphical representation of the 
experimental design is given in Figure 1.
2.3 | Behavioral assessment
All behavioral tests were performed when mice reached 12 
months of age and immediately prior to sacrifice. A visual 
placing test was performed on each animal on the first day of 
testing, to ensure animals were not visually impaired.27
Spatial learning and memory were evaluated with the 
Barnes Maze as previously described.28 Briefly, the maze 
consisted of a brightly illuminated (800 lux lighting) circular 
platform (92 cm diameter), with 20 evenly distributed holes 
located around the circumference and visual cues (4 simple 
shapes) placed at the periphery. The experiment was con-
ducted over a 5- day period, with each mouse tested/trained 
on ability to locate the escape box four times per day during 
days 1- 4. On day 5, a probe test was conducted, the maze 
was rotated 90°, the escape box was removed, and mice were 
placed in the center of the maze in which they were free to 
navigate for 1 minute. Percentage time in the correct quad-
rant was determined using the Smart 3.0 tracking software 
(Panlab, Kent, UK).
The novel object recognition (NOR), a measure of recog-
nition memory, was performed as described previously,29,30 
with slight modifications. Briefly, on day 1 mice were habit-
uated in gray 50 × 50 × 50 cm apparatus illuminated with low 
lux 100 lux lighting, mice were placed into the empty maze, 
and allowed to move freely for 10 minutes. On day 2, mice 
were conditioned to a single object for a 10- minute period. 
On day 3, mice were placed into the same experimental area 
in the presence of two identical objects for 15 minutes, after 
which they were returned to their respective cages and an 
inter- trial interval of 1 hour was observed. One familiar ob-
ject was replaced with a novel object. Mice were placed back 
within the testing area for a final 10 minutes. Videos were 
analyzed for a 5- minute period, after which if total object ex-
ploration time failed to reach an accumulative 10 seconds, 
analysis continued until the 10 seconds was met. Animals 
not achieving 10 seconds were excluded from the analysis.31 
Similarly, animals not achieving a cumulative 10 seconds 
with the familiar object were excluded. Discrimination index 
was calculated as follows: DI = (TN − TF)/(TN + TF), where 
TN is the time spent exploring the novel object and TF is the 
time spent exploring the familiar object.
Y- maze spontaneous alternation test, a measure of spatial 
working memory was performed on the final day of behav-
ioral testing as previously described.32 Briefly, the Y- maze 
apparatus comprised of white Plexiglas in the following 
F I G U R E  1  Experimental overview. At 4 months of age APOE4 and APOE3 TR mice were provided with a high- fat diet to model a western 
style diet. At 8 months of age mice received i.p. injections with 160 mg/kg VCD for 14 days in order to deplete ovarian follicles and mimic 
menopause by 12 months of age. At 12 months of age, mice were assessed cognitively through a battery of behavioral tests including Barnes maze, 
Y- maze, and object recognition. Upon completing the behavioral tests animals were immediately sacrificed. Created with BioRender.com
4 of 16 |   PONTIFEX ET al.
dimensions (38.5 × 8 × 13 cm, spaced 120° apart) was illu-
minated with low lux (100 lux) lighting. Mice were placed 
into the maze and allowed to explore freely for 7 minutes 
while tracking software recorded zone transitioning and lo-
comotor activity (Smart 3.0 tracking software, Panlab, Kent, 
UK). Spontaneous alternation was calculated using the fol-
lowing formula: Spontaneous Alternation = (Number of al-
ternations/Total Arm entries − 2) × 100.
2.4 | Histological analysis
Ovaries were trimmed of fat and fixed in 10% formalin for 
24  hours before being paraffin- embedded, and processed 
for hematoxylin and eosin (H&E) staining as described 
previously.33
2.5 | Fatty acid profile in the brain
Total lipids were extracted from sub- cortical brain tissues 
(n  =  5/6 per group) using the Folch extraction method.34 
Fatty acid methyl esters (FAME) were obtained using acid- 
catalyzed transesterification.35 FAME were evaporated under 
oxygen- free nitrogen, and re- suspended in 500 µL of iso- 
hexane, SPE silica cartridges (Clean- up 203 Cusil 156, UCT) 
were used for purification purposes. The purified FAMEs 
were separated by gas chromatography using a Trace 1300 se-
ries Gas Chromatograph (Thermo Fisher Scientific, Stafford 
House, Boundary Way, Hemel Hempstead. HP2 7GE, U.K.) 
equipped with a PTV injector modified for on- column injec-
tion, and a flame ionization detector. A fused silica capil-
lary column (TraceGOLD TG- 5MS Guard GC Column with 
SafeGuard column, 30 m × 0.32 mm × 0.25 µm; Thermo 
Fisher Scientific, Hemel, Hempstead, UK) was employed, 
and hydrogen was used as carrier gas. The temperature gradi-
ent was from 50 to 150°C at 40°C/min and then, to 200°C at 
2°C/min followed by 214°C at 1°C/min and finally to 220°C 
at 40°C/min, where it was held for 5 min. Individual methyl 
esters were identified by comparison to known standards 
(Marine oil FAME mix RESTEK #35066). Data were col-
lected and processed using the Chromeleon software package 
(version 7.2).
2.6 | Immunoblotting and ELISA
Cortices were homogenized in lysis buffer (CelLytic MT, 
Sigma- Aldrich, UK) containing protease (cOmplete, Mini, 
EDTA- free Protease Inhibitor Cocktail, Roche, UK) and 
phosphatase (PhosSTOP, Roche, UK) inhibitors. Protein 
concentration was determined using the Pierce BCA 
Protein Assay Kit (Thermo Fisher Scientific, UK). Protein 
electrophoresis was conducted under denaturing condi-
tions as previously described.36 The following antibodies 
were used: anti- APOE (1:1000; Cell Signaling, UK), anti- 
phospho- mTOR (Ser2448) (1:1000; Cell Signaling, UK), 
anti- mTOR, (1:1000; Cell Signaling, UK), anti- phospho- 
ERK1/2 (Thr202/Tyr204) (1:1000; Cell Signaling, UK), anti- 
ERK1/2, (1:1000; Cell Signaling, UK) anti- GAPDH (1:2500, 
Cell Signaling, UK), anti- beta- actin (1:2500, Cell Signaling, 
UK), and anti- Rabbit IgG (H + L) DyLight 680 Conjugate 
(1:10,000, Cell Signaling, UK). Bands were revealed by flu-
orescence using an Odyssey 9120 Infrared Imaging system 
(LI- COR Biosciences, Ltd, UK). Relative band intensities 
were quantified using Image studio software Version 5.2.5 
(LI- COR Biosciences, Ltd, UK).
Follicle- stimulating hormone (FSH) concentrations were 
determined by ELISA (Abnova, Taipei, Taiwan; ref KA2330) 
in sera samples as per the manufacturer’s instructions and 
are displayed as ng/mL. Brain- derived neurotrophic fac-
tor (BDNF) concentrations were determined using DuoSet 
ELISA kit (R&D systems Minneapolis, MN, USA; ref 
DY248) from brain homogenates, as per the manufacturer’s 
instructions, and the concentration (pg/mL) was normalized 
to total protein content (pg/mg total protein).
2.7 | RNA isolation and qRT- PCR
RNA isolation, cDNA synthesis, and qRT- PCR were carried 
out as previously described.37 Briefly, total RNA was isolated 
from the brain samples using the Qiazol reagent (Qiagen, UK). 
One μg of total RNA was treated with DNase I (Invitrogen, UK) 
and used for cDNA synthesis using Invitrogen Oligo (dT) prim-
ers and M- MMLV reverse transcriptase. Quantitative real- time 
PCR (qRT- PCR) reactions were performed using SYBR green 
detection technology on the Roche light cycler 480 (Roche 
Life Science, UK). Results are expressed as relative quantity 
scaled to the average across all samples per target gene and 
normalized to the reference gene glyceraldehyde 3- phosphate 
dehydrogenase (Gapdh), which was identified as the optimal 
housekeeping selection using the software RefFinder.38 Primer 
sequences are given in Supplementary Table S2.
2.8 | Statistical analysis
All data are presented as mean ± S.E.M. Data analysis was 
performed in GraphPad Prism version 8 (GraphPad Software, 
CA, USA). After identifying outliers using the Grubbs method, 
data were checked for normality/equal variances, perform-
ing log or box- cox transformation if necessary. Comparisons 
among groups were performed on normally distributed data 
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using two- way ANOVA, followed by post hoc Tukey’s test 
when two- way ANOVA resulted in a significant interaction 
effect. Pearson’s correlation was used in behavioral analy-
sis to assess the association of travel distance and movement 
speed on corresponding behavioral test performance. P values 
of less than .05 were considered statistically significant.
3 |  RESULTS
3.1 | Repeated injections of VCD result 
in ovarian failure independently of APOE 
genotype
Repeated injections of VCD in APOE3- TR and APOE4- TR 
mice resulted in a considerable loss of ovarian follicles 
(Figures 2A and S1) and a fourfold increase in serum FSH 
levels (VCD effect: F(1, 21) = 27.64 P < .0001 Figure 2B), 
irrespective of APOE genotype. Neither VCD treatment nor 
genotype had any impact on body weight gain (P > .05 Figure 
2C) nor food intake (P > .05; Supplementary Figure S2).
3.2 | While APOE4 impairs working spatial 
memory, VCD causes additional deficits to 
recognition memory
Y- maze, Barnes maze, and NOR were employed to estab-
lish the impact of genotype and VCD treatment on cognitive 
performance (Figure 3). VCD had no effect on spatial learn-
ing and memory tasks, as assessed by the Y- maze and the 
Barnes maze (Figure 3A,B). However, a genotype- dependent 
effect was observed, with APOE4 animals displaying ~12% 
lower cognitive performance than their APOE3 counterparts 
as assessed by the Y- maze (genotype effect: F(1, 38) = 7.75 
P < 0.01 Figure 3A). This was consistent with the Barnes 
maze, where APOE4 animals spent ~40% less time in the 
correct quadrant, (genotype effect: F(1, 37) = 8.09 P < .01 
Figure 3B). A genotype effect was also apparent during the 
learning phase (Supplementary Figure S3). Pearson’s cor-
relation revealed that these effects were not influenced by 
movement speed nor travel distance ruling out these as po-
tential confounding factors (Figure 3C- F) Representative tra-
jectory maps for Barnes probe test are shown in Figure 3G.
F I G U R E  2  VCD treatment leads to 
ovarian failure independently of APOE 
genotype in APOE3- TR and APOE4- TR 
mice. A, Representative images of APOE3- 
TR and APOE4- TR female mice ovaries 
stained with hematoxylin and eosin show 
important loss of ovarian follicles following 
repeated i.p. injections of VCD (arrows 
indicate follicles); B, VCD- injected groups 
display elevated serum follicle- stimulating 
hormone (FSH) levels (n ≥ 5); C, Body 
weight was unaffected by VCD treatment 
or genotype (n ≥ 8); Data are presented 
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F I G U R E  3  APOE4 and VCD treatment influence cognition. A, Y- maze spontaneous alternation task (n ≥ 8) and B, Barnes probe test (n ≥ 8) 
identify deficits in spatial memory as a result of APOE4 genotype, VCD treatment had no impact; C- F, Pearson’s Correlation: Analysis of travel 
distance and movement speed do not correlate with Y- maze nor Barnes maze performance P > .05; G,Representative trajectory’s from APOE3 
Sham (left) and APOE4 sham (right) during the probe test, circle denotes former location of the escape box; H, Performance on Novel Object 
Recognition task (n ≥ 7) was severely compromised in the APOE4 VCD group; I and J, Object recognition test score did not correlate with travel 
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Unlike spatial learning and memory, recognition memory 
as assessed by the NOR test was influenced by the meno-
pausal status, and in a genotype- dependent manner, with 
VCD- injected APOE4 animals losing the ability to dis-
tinguish between novel and familiar objects (VCD effect: 
F(1, 31) = 5.40 P < .05, Interaction effect: F(1, 31) = 5.52 
P < .05 Figure 3H). Again, these effects were not influenced 
by movement speed nor travel distance (Figure 3I,J).
3.3 | VCD injections reduce brain DHA 
levels independently of APOE genotype
A significant 13% genotype independent lower brain DHA 
concentration was observed in VCD- injected animals inde-
pendent of their APOE genotype (VCD effect: F(1, 18) = 
17.94 P <  .001 Figure 4A). Higher total mono- unsaturated 
fatty acids (MUFAs) were observed in APOE3 carriers 
F I G U R E  4  HF VCD treatment reduces brain DHA levels. A, GC- FID analysis revealed lower brain DHA levels in VCD- treated groups 
(n = 5/6); B- F, Expression of the key transporter Aclsl6, Fatp4, Fatp1, Mfsd2a, and Fabp5 involved in DHA transport and uptake at the blood- brain 



































































































































APOE3 APOE4 APOE3 APOE4 APOE3 APOE4






















HF SHAM HF VCD
HF SHAM HF VCD HF SHAM HF VCD HF SHAM HF VCD
HF SHAM HF VCD HF SHAM HF VCD
8 of 16 |   PONTIFEX ET al.
following VCD injections (VCD effect: F(1, 18) = 6.44 
P < .05; Interaction effect: F(1, 18) = 7.66 P < .05; Table 
1). These changes were mirrored by a nominal decrease in 
total saturated fatty acids (SFAs) in APOE3 (VCD effect: 
F(1, 18) = 3.03 P <  .1; Interaction effect: F(1, 18) = 4.23 
P  =  .05). In addition, DHA: AA ratio was lower follow-
ing VCD treatment (VCD effect F(1, 17) = 4.49 P <  .05). 
Although no interaction was detected, DHA: AA ratio was 
8% lower in APOE4 animals but remained constant in APOE3 
regardless of treatment.
To identify whether the observed lower DHA related to 
deficits in DHA transport, gene expression profiles of key 
DHA transporters in the brain were assessed. Interestingly, a 
member of the long- chain acyl- CoA synthetase family Acsl6 
known to be highly abundant in the brain39 and present in 
brain microvessels,40 was reduced by 10% in VCD- treated 
animals (VCD effect: F(1, 20) = 4.76 P <  .05 Figure 4B). 
Expression of the predominant fatty acid transport proteins 
in the BBB endothelial cells, Fatp4 and Fatp1,41 was also 
determined. Fatp4 expression was 14% lower as a result of 
APOE4 genotype, with the reduction particularly evident in 
APOE4 VCD- treated animals although the interaction did not 
reach significance (genotype effect: F(1, 20) = 9.29 P < .01; 
Interaction effect: F = 3.35 P = .08 Figure 4C). A similar 
genotype trend was observed for Fatp1 (P = .069 Figure 3D), 
while no effect was observed for major facilitator superfamily 
domain- containing 2a Mfsd2a or fatty acid- binding protein 5 
Fabp5 (Figure 4E,F).
3.4 | VCD injections and APOE4 trigger 
lower synaptic plasticity response
Both APOE4 genotype and VCD administration led to di-
minished BDNF levels in the brain (VCD effect: F(1, 19) = 
7.24 P < .05; genotype effect: F(1, 19) = 5.96 P < .05 Figure 
5A). Lower ApoE protein levels were observed in APOE4 
compared to APOE3 animals (genotype effect: F(1, 20) = 
55.90 P < .0001; Figure 5B). Phosphorylation of mechanistic 
target of rapamycin (mTOR) was significantly influenced by 
VCD treatment and genotype (VCD effect: F(1, 20) = 5.17 
P < .05; genotype effect: F(1, 20) = 5.86 P < .05 Figure 5C). 
APOE4 genotype and its interaction with VCD resulted in 
impaired extracellular signal- regulated kinase (ERK) phos-
phorylation, with both ERK1 (interaction effect: F(1,20) = 
10.28 P  <  .01; genotype effect: F(1, 20)  = 6.79 P  <  .05 
Figure 5D) and ERK 2 (interaction effect: F(1,20)  = 9.51 
P  <  .01; genotype effect: F(1, 20) = 3.19 P  =  .09 Figure 
5D) affected. At the transcriptional level only genotype in-
fluenced mTOR expression (genotype effect: F(1, 20) = 6.97 
P  <  .05; Figure 5E), however its upstream activator, Akt 
was downregulated in a VCD*genotype- dependent manner 








P valueHF Sham HF VCD HF Sham HF VCD
Total n- 3 PUFA 13.30 ± 0.20 11.60 ± 0.70 13.20 ± 0.30 11.80 ± 0.50 0.964 0.004 0.805
20:5 n- 3 (EPA) 0.02 ± 0.01 0.03 ± 0.01 0.02 ± 0.01 0.03 ± 0.01 0.892 0.315 0.978
22:6 n- 3 (DHA) 13.20 ± 0.20 11.20 ± 0.50 13.10 ± 0.30 11.70 ± 0.50 0.650 >0.001 0.519
Total n- 6 14.20 ± 0.20 12.60 ± 0.40 14.80 ± 0.90 13.20 ± 0.60 0.274 0.011 0.979
20:4 n- 6 (AA) 9.37 ± 0.21 8.10 ± 0.39 8.95 ± 0.25 8.67 ± 0.50 0.860 0.058 0.221
DHA:AA 1.40 ± 0.03 1.39 ± 0.05 1.48 ± 0.01 1.36 ± 0.03 0.619 0.049 0.134
Total SFAs 38.70 ± 0.40a 35.50 ± 0.90b 36.60 ± 0.60 36.90 ± 1.20 0.689 0.098 0.054
16:0 17.60 ± 0.50a 14.70 ± 0.70b§ 16.20 ± 0.50 17.30 ± 0.90§ 0.406 0.207 0.010
18:0 20.10 ± 0.30 18.90 ± 0.50 19.30 ± 0.20 18.30 ± 0.60 0.138 0.025 0.802
20:0 0.31 ± 0.02 0.41 ± 0.03 0.28 ± 0.02 0.33 ± 0.03 0.053 0.014 0.343
22:0 0.15 ± 0.05a 0.38 ± 0.05b 0.26 ± 0.01 0.19 ± 0.06 0.165 0.552 0.007
Total MUFAs 25.40 ± 0.40a 30.50 ± 0.80b 27.30 ± 0.90 27.90 ± 1.40 0.448 0.021 0.013
18:1 n- 9 18.20 ± 0.50 21.20 ± 0.80 19.30 ± 0.60 19.30 ± 1.20 0.684 0.091 0.084
20:1 n- 9 2.03 ± 0.18a 3.04 ± 0.20b 2.28 ± 0.20 2.21 ± 0.21 0.166 0.028 0.013
24:1 n- 9 1.37 ± 0.09a 1.96 ± 0.18b§ 1.56 ± 0.11 1.14 ± 0.24§ 0.080 0.641 0.008
Note: (n = 5/6 per group). Data are % of total fatty acids and mean value ± S.E.M. Two- way ANOVA. Letters a and b denote significant difference between 
intervention while § denotes significant genotype effect as analyzed via post hoc. Bold values denote significant values. The full table can be found in supplementary 
data (Table S3).
Abbreviations: DHA:AA, Docosahexaenoic acid to Arachidonic acid ratio; MUFAs, Monounsaturated fatty acids; PUFA, Polyunsaturated fatty acid; SFAs, Saturated 
fatty acids; 20:5 n- 3 EPA, Eicosapentaenoic acid; 22:6 n- 3 DHA, Docosahexaenoic acid; 20:4 n- 6 AA, Arachidonic acid; 16:0, Palmitic acid; 18:0, Stearic acid; 20:0, 
Eicosanoic acid; 22:0, Docosanoic acid; 18:1 n- 9, Oleic acid; 20:1 n- 9, 11- Eicosenoic acid; 24:1 n- 9, Nervonic acid.
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(interaction effect: F(1, 20) = 5.49 P < .05; genotype effect: 
F(1, 20) = 7.31 P < .05 Figure 5F). VCD and APOE4 geno-
type resulted in further synaptic plasticity- related signaling 
deficits (Figure 5H- M). The transcription factor cAMP re-
sponsive element- binding protein 1 (Creb1) was downregu-
lated in APOE4 animals (genotype effect: F(1, 19) = 11.56 
P < .01; Figure 5G) while its fellow CREB family member, 
the activating transcription factor 4 (Atf4) was downregulated 
in response to VCD treatment (VCD effect F 1, 20) = 14.95 
P <  .001; Figure 5H). Interestingly, the downstream target 
activity- regulated cytoskeleton- associated protein (Arc) was 
nominally reduced ~2- fold in APOE4 VCD- treated animals, 
F I G U R E  5  Selective impact of genotype and VCD on synaptic plasticity- related genes and proteins; A, ELISA revealed a reduction in BDNF 
protein levels as a result of VCD insult and APOE genotype; B, ApoE protein was lower in the cortex of APOE4 animals; C, p- mTOR was lower 
in APOE4 VCD- treated animals; D, p- ERK was reduced as a result of APOE4 genotype and VCD*genotype interaction and particularly reduced 
in APOE4 VCD- treated animals; representative western blots are given below each graph (n = 6); E- L, Hippocampal expression profiles relating 
to synaptic plasticity (n = 6); E- F, in which genotype and VCD- mediated reductions in mTOR and Akt; G- I, resulted in diminished Creb1, 




(E) (F) (G) (H)
(I) (J) (K) (L)
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although this did not reach significance. Ephrin type- B re-
ceptor 2 (Ephb2) was significantly impacted by the interac-
tive impact of APOE4*VCD, resulting in a ~30% reduction 
in APOE4 VCD- treated animals compared to APOE4 sham 
or APOE3 counterparts (interaction: F(1, 20) = 7.67 P < .05; 
VCD effect: F(1, 20) = 5.97 P  <  .05; genotype effect: 
F(1, 20) = 14.05 P < .01; Figure 5J). In addition to this, fur-
ther genotype effects were apparent for Fos (genotype effect: 
F(1, 20) = 9.23 P < .05 Figure 5K) and the cannabinoid re-
ceptor Cnr1 (genotype effect: F(1, 20) = 6.84 P < .05 Figure 
5L).FIGURE 5 (Continued)
4 |  DISCUSSION
Several studies report that female carriers of the APOE4 
genotype are at a higher risk of AD,8 however little is known 
as to how this predisposition manifests.17 Here, we sought 
to determine whether the cumulative APOE4*menopause 
effect contributes toward this greater risk. With VCD treat-
ment emerging as a robust model to assess the implications 
of menopause in neurological disease,23 we investigated for 
the first time the impact of VCD- mediated ovarian failure 
in the APOE- TR mouse model, focusing on cognition, brain 
fatty acid profiles, and synaptic plasticity- related signaling. 
Deficits in spatial learning and memory were related to the 
APOE4 genotype, with an additive effect of menopause and 
APOE4 carrier status on recognition memory. Furthermore, 
the VCD insult lowered brain DHA status while both factors 
influenced synaptic plasticity- related signaling genes and 
proteins.
Unlike previously published data by us and others report-
ing a strong impact of APOE4 genotype on body weight gain 
in male mice,42,43 no effect of APOE genotype nor VCD in-
jections was observed in our female mice. This observation is 
in agreement with previous reports indicating limited impact 
of menopause44 and APOE445 on body weight gain in female 
mice.
Y- maze and Barnes maze revealed APOE4- dependent 
deficits in spatial learning and memory. Deficits in spatial 
memory performance mediated via APOE4 genotype have 
been reported in several studies.46- 48 Interestingly, the extent 
of the deficit appears to be greater in APOE4 female mice 
or absent in APOE4 male mice.46 No exacerbation of spatial 
deficits were detected as a result of menopause in agreement 
with reports indicating that the impact on spatial memory is 
subtle,49 and dependent upon age, which represents a key fac-
tor in the extent of decline.50 Conversely, recognition memory 
was significantly influenced by the menopause mimic VCD 
with the effect restricted to APOE4 animals. Impairment of 
recognition memory has been previously reported in chronic 
ovariectomized C57BL/6 mice,51 and aged rhesus monkeys,52 
suggesting that the medial temporal lobe and surrounding 
cortical areas are particularly sensitive to ovarian failure. 
Interestingly, we report that this effect was exacerbated by 
the APOE4 genotype, highlighting this specific brain area as 
a focus for future endeavors. Together, the behavioral test re-
sults indicate both genotype- and genotype*VCD- mediated 
cognitive deficits and show how the combination of factors 
result in broader cognitive impairment.
Reduced DHA intake and status are associated with neu-
ropathology, cognitive decline, and higher AD risk.15,53,54 
Both APOE4 and ovarian function impact n- 3 PUFA and 
DHA homeostasis.55- 58 To the best of our knowledge, the 
combined impact of both ovarian failure and APOE4 gen-
otype on brain DHA levels has not been previously ex-
plored. Here, brain DHA levels were equally diminished in 
both genotypes following VCD treatment. Interestingly, we 
observed lower brain ApoE levels in both APOE4 groups, 
independent of VCD insult, suggesting DHA concentra-
tion was uncoupled from ApoE protein levels. This con-
trasts a previous report indicative of ApoE involvement in 
brain DHA levels,55 however as previously mentioned, this 
may be sex- dependent and more prominent in male mice. 
Although this is the first time brain fatty acid levels have 
been analyzed in an APOE- TR VCD model, results from 
OVX models demonstrate similar reductions in DHA,59 in-
dicating a clear relationship between reproductive hormones 
and brain DHA maintenance. Surprisingly, the reduction in 
DHA did not translate to an observable behavioral deficit in 
APOE3- treated animals suggesting that protection/tolerance 
is conferred by APOE3, perhaps via a compensatory mech-
anism. For example, the DHA:AA ratio in APOE4 VCD- 
treated animals was more extensively reduced, offering one 
possible explanation for the greater resilience shown by their 
APOE3 counterparts. Indeed, the importance of DHA:AA as 
a determinant of neuro- inflammatory status, given that AA 
and DHA are precursors of potent pro- inflammatory eico-
sanoids60 and specialized pro- resolving mediators, respec-
tively,12,61 offers a plausible mechanistic basis. Furthermore, 
in APOE3 the VCD- mediated fluctuations of higher total 
MUFA and lower total SFA (absent in APOE4) may have 
influenced cognition to some extent. Higher MUFA intake 
has been previously shown to improve the brain function 
while lower MUFA brain levels are associated with AD, 
aging, and depression.62 A number of pathways have been 
proposed to explain the benefits of MUFAs including the 
maintenance of membrane flexibility63 and the actions of 
MUFA’s as anti- inflammatory and antioxidant derivatives64 
which have been shown to modulate the neuroinflammation 
in ApoE KO mice.65
Although the mechanism by which DHA enters the brain 
(passive/active) remains to be fully determined, current evi-
dence points out it is likely to be in part mediated by a small 
number of specific binding/transporter proteins. MFSD2A, 
ACSL6, FABP5, and the FATPs 1 and 4 are expressed at 
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the BBB40 and have been previously associated with DHA 
transport into the brain.17 Of the DHA transporters measured, 
Acsl6 described from knockout studies as being a key media-
tor of neuroprotective DHA within the brain39 and believed to 
be critical in maintaining brain DHA levels,66 was downreg-
ulated in response to VCD treatment. Acls6 may, therefore, 
account for the reduction in DHA observed and should be a 
focus for future studies evaluating the impact of menopause 
on brain DHA levels. Fatp1, but particularly Fatp4 displayed 
genotype deficits; these fatty acid transporters have been 
shown to bind DHA and facilitate its transport across the en-
dothelial cell membrane.67 This lower expression may in part 
explain the genotype reductions in DHA observed by other 
groups particularly if exacerbated by age. Previous work has 
indicated that blood- brain barrier transporter protein cell lo-
calization and membrane shedding are influenced by APOE 
and neuropathology. This could also influence the capacity 
to uptake DHA into the brain.68,69 Moreover, as previously 
mentioned the change may be independent of transport and 
instead relate to metabolic disturbances which lead to greater 
β- oxidation of DHA.70 This is conceivable given the role es-
trogens play in bioenergetic systems within the brain.71,72
Given the role of ApoE protein in neurite outgrowth73 
and neuronal repair processes,74 APOE4- specific reductions 
in spatial memory might be expected in light of the dimin-
ished protein levels observed in this experimentation. Further 
investigation may be warranted to establish if these lower 
APOE4 levels are constant across sexes given that spatial 
memory deficits appear to be APOE4 female specific.46 As 
with human menopause, VCD treatment is associated with 
increased FSH levels. Research evaluating the impact of el-
evated FSH on cognition is limited, however in OVX mice a 
reduction of all gonadotropins, appears equally as effective 
at preserving cognition as providing estrogen.75 Additionally, 
in humans FSH:estradiol has been used as a predictor of 
MCI.76 Moreover, estrogen is a well- established regulator 
of synaptic plasticity in key areas of the brain including the 
hippocampus.77
In this study, we observed that both the menopause 
mimic and APOE4 genotype influenced synaptic signal-
ing in the in the brain. First, the brain neurotrophic factor 
BDNF, described to be multifaceted and considered a flex-
ible hub for synaptic plasticity and cognitive functioning78 
was reduced as a result of APOE4 genotype and VCD treat-
ment. Such observation is in agreement with previous stud-
ies focusing on APOE479 and VCD treatment separately.80 
Interestingly BDNF is known to influence both mTOR 
and ERK activation.81 mTOR signaling was impaired by 
the APOE4*VCD combination. To the best of our knowl-
edge, such an effect has not been previously reported in 
APOE4 mice, but the effect of menopause has been ob-
served in OVX models.82- 84 mTOR activation, likely trig-
gered via the PI3K- AKT pathway, is critical for neuronal 
cell survival, and is intriguingly associated with mainte-
nance of glucose homeostasis, with similar deficits estab-
lished in the diabetic rat brain,85 thus highlighting potential 
metabolic/bioenergetic disturbances in the APOE4 VCD- 
treated brain. Furthermore, AKT and mTOR activation in 
AD mouse models ameliorates deficits in synaptic plas-
ticity improving associated learning and memory.86,87 It 
is, therefore, possible that the impaired object recognition 
performance observed in this study stems from impairment 
of PI3K- AKT- mTOR signaling, which is already known to 
be estrogen and ER sensitive.77 ERK signaling represents 
another important cascade which is similarly intertwined 
with BDNF and synaptic plasticity.88 ERK activation was 
found to be reduced as a result of APOE4 genotype and 
the interactive impact of VCD and genotype. This is in 
line with Yong and colleagues who reported diminishing 
ERK phosphorylation in aging female APOE4- TR mice.89 
Interestingly both Yong and our group show a reduction 
in brain APOE protein levels in the APOE4 female mice, 
highlighting how this may be coupled to ERK phosphory-
lation. Additionally, ERK activation has been reported in 
OVX studies.90,91 Given DHA’s proposed influence upon 
both PI3K- AKT- mTOR92 and ERK signaling pathways,93 
the altered DHA/PUFA status associated with VCD treat-
ment, and the subsequent reduction in BDNF may offer a 
plausible mechanistic basis for their disruption, although 
further confirmatory experiments are required. As dis-
cussed mTOR and ERK are central components of synap-
tic plasticity- related signaling and are involved in various 
down- stream pathways explaining the diminished tran-
scription of the CREB family transcription factors (Creb1 
and Atf4), both of which have integral roles in synaptic 
plasticity.94,95 Further down- stream effects reflected previ-
ous observations with Arc expression nominally reduced in 
APOE4, particularly VCD- treated animals. Referred to as 
the master organizer of long- term synaptic plasticity,96 Arc 
has been reportedly regulated by both APOE4 and estro-
gen with both MAPK and PI3K pathways implicated.97,98 
We also noted diminished Ephb2 expression as a result of 
the APOE4*VCD interaction. Interestingly, Ephb2 plays a 
fundamental role in learning and memory, with implica-
tions ranging from synapse maintenance and synaptogene-
sis to AMPA and NMDA receptor expression, localization, 
and function.99- 103 Indeed, increased Ephb2 expression 
has been found to compensate for AD- related NMDA re-
ceptor impairment.104 Ephb2, therefore, offers additional 
mechanistic basis for the cognitive impairment associated 
with APOE4*VCD. Further to this, APOE4 genotype led 
to a downregulation of Fos an indicator for neuronal acti-
vation,105 and may be linked to the altered ERK signaling 
profile to which it is known to be influenced.106 Finally, 
with implications in hippocampal synaptic plasticity, adult 
neurogenesis, and subsequent memory consolidation we 
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assessed endocannabinoid, specifically Cnr1 regulation.107 
An APOE4- dependent reduction in Cnr1 expression was 
observed, CNR1 receptor antagonism and subsequent en-
docannabinoid dysregulation has been associated with defi-
cits in learning and memory.108 Recently CNR1 activation 
has been reported to be neuroprotective conferring specific 
improvement in spatial memory,109 therefore, diminished 
CNR1 may also contribute to the spatial memory deficits 
associated with APOE4. Research connecting APOE and 
endocannabinoid signaling, particularly within the brain is 
surprisingly limited, and warrants further investigation in 
light of these results.
As with all animal models some limitations associated 
with the model system should be mentioned. First, although 
well- established,23 particularly in cognitive and cardiol-
ogy research24,110,111 and believed to be non- toxic/ovarian 
follicle specific,24,112 the VCD menopause induction may 
introduce as yet unidentified off- target impacts. The tim-
ing of the VCD and cognitive assessment (ie, middle- aged 
animals) could have resulted in some sham animals being 
spontaneously acyclic. However, given that VCD was in-
troduced before natural ovarian failure is known to occur in 
C57BL/6 mice,25,113 and that we observed primordial fol-
licles in sham animals (Figure S1), the risk of this is low, 
consistent with the increase in FSH levels in only VCD- 
treated animals.114,115 Furthermore, even if some animals 
had become partially senescent over the later stage of the 
assessment period, the VCD- treated animals would have 
undergone the process much earlier and thus would have 
been exposed to the detrimental effects of ovarian failure 
for a longer duration of time.
5 |  CONCLUSION
Despite its well- established impact on late- onset AD risk, the 
etiological basis of the APOE4 genotype- associated cognitive 
deficits and neuropathology remains elusive. Sex, and meno-
pausal status remain overlooked factors that likely influence 
the progression of neurological diseases such as AD. Here 
we provide evidence of menopause- related risk and suggest 
a greater sensitivity in APOE4 carriers, with APOE4 carriers 
displaying greater cognitive impairment and more extensive 
deficits in synaptic plasticity- related signaling.
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